Nanoformulations-based advancement in the delivery of phytopharmaceuticals for skin cancer management

Skin carcinoma is a dynamically increasing serious illness worldwide which impacts global health wellbeing. Synthetic chemotherapeutic drugs have high efficacy, but recently more adverse effects and drug resistance issues have been reported. Moreover, and due to the non-specific targeting, synthetic chemotherapeutic agents kill the healthy cells along with the cancerous cells. Hence due to the unique role of the phytopharmaceuticals in the treatment of skin cancer by targeting multiple molecular pathways without affecting the other healthy cells, they are the future of skin cancer management. Simultaneously nano-based drug delivery improves the efficiency, target specificity, and safety profile of phytopharmaceuticals due to the maximum bioavailability and specific targeting at the disease site. This review offers an extensive viewpoint of the present statistical status of skin carcinoma globally, and preclinical stages of phytopharmaceutical-based nanoformulations have also been summarized.

Automated summary

Skin carcinoma is a serious global disease, with synthetic chemotherapeutic drugs being effective but causing more adverse effects and drug resistance. Phytopharmaceuticals, on the other hand, target multiple molecular pathways without affecting healthy cells, making them the future of skin cancer treatment. Nano-based drug delivery improves the efficiency and safety of phytopharmaceuticals by enhancing bioavailability and specific targeting at the disease site.